SynthesisPloS one2014
Oral Chinese herbal medicine combined with pharmacotherapy for stable COPD: a systematic review of effect on BODE index and six minute walk test.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Efficacy and safety of oral proprietary Chinese medicines in the treatment of stable chronic obstructive pulmonary disease: a network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Trial
- Concurrent Chinese and Western medication use and risk of acute exacerbations in chronic obstructive pulmonary disease: A national cohort study.Integrative medicine research · 2026Article
- Therapeutic Mechanism of Yihuo Huatan Formula in Stable Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial Integrating Metabolomics and 16S rRNA Gene Sequencing.Chinese journal of integrative medicine · 2026Article
- Advances in Traditional Chinese Medicine for chronic obstructive pulmonary disease through multi-omics approaches.Frontiers in cell and developmental biology · 2026Review
- Patients' Preferences Regarding Traditional Chinese Medicine for the Treatment of Chronic Obstructive Pulmonary Disease: Protocol for a Mixed Methods Study.JMIR research protocols · 2025Article
- Herbal Treatment of COPD and Asthma According to Persian Medicine: a Review of Current Evidence.Tanaffos · 2023Review
- Current status of herbal medicine research for respiratory diseases induced by particulate matter: a protocol for a scoping review.Systematic reviews · 2022Article
- Case Report: Kampo Medicine for Non-tuberculous Mycobacterium Pulmonary Disease.Frontiers in nutrition · 2021Article
- Chinese Medicine for Chronic Obstructive Pulmonary Disease: A Pilot Study on Patient Preferences.Patient preference and adherence · 2021Article
- Feikang granules ameliorate pulmonary inflammation in the rat model of chronic obstructive pulmonary disease via TLR2/4-mediated NF-κB pathway.BMC complementary medicine and therapies · 2020Article
- Mechanism of Action of Bu-Fei-Yi-Shen Formula in Treating Chronic Obstructive Pulmonary Disease Based on Network Pharmacology Analysis and Molecular Docking Validation.BioMed research international · 2020Article
- Article
- Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.Pharmacology & therapeutics · 2019Review
- A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic obstructive pulmonary disease.Medicine · 2018Article
- Nucleosides isolated fromInternational journal of chronic obstructive pulmonary disease · 2018Article
- Review
- Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.International journal of oncology · 2017Article
- The inhibitory mechanism of Cordyceps sinensis on cigarette smoke extract-induced senescence in human bronchial epithelial cells.International journal of chronic obstructive pulmonary disease · 2016Article
- Dual-Directional Immunomodulatory Effects of Corbrin Capsule on Autoimmune Thyroid Diseases.Evidence-based complementary and alternative medicine : eCAM · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review evaluated the effects of Chinese herbal medicine (CHM) plus routine pharmacotherapy (RP) on the objective outcome measures BODE index, 6-minute walk test (6MWT), and 6-minute walk distance (6MWD) in individuals with stable chronic obstructive pulmonary disease (COPD). Searches were conducted of six English and Chinese databases (PubMed, EMBASE, CENTRAL, CINAHL, CNKI and CQVIP) from their inceptions until 18th November 2013 for randomized controlled trials involving oral administration of CHM plus RP compared to the same RP, with BODE Index and/or 6MWT/D as outcomes. Twenty-five studies were identified. BODE Index was used in nine studies and 6MWT/D was used in 22 studies. Methodological quality was assessed using the Cochrane Risk of Bias tool. Weaknesses were identified in most studies. Six studies were judged as 'low' risk of bias for randomisation sequence generation. Twenty-two studies involving 1,834 participants were included in the meta-analyses. The main meta-analysis results showed relative benefits for BODE Index in nine studies (mean difference [MD] -0.71, 95% confidence interval [CI] -0.94, -0.47) and 6MWT/D in 17 studies (MD 54.61 meters, 95%CI 33.30, 75.92) in favour of the CHM plus RP groups. The principal plants used were Astragalus membranaceus, Panax ginseng and Cordyceps sinensis. A. membranaceus was used in combination with other herbs in 18 formulae in 16 studies. Detailed sub-group and sensitivity analyses were conducted. Clinically meaningful benefits for BODE Index and 6MWT were found in multiple studies. These therapeutic effects were promising but need to be interpreted with caution due to variations in the CHMs and RPs used and methodological weakness in the studies. These issues should be addressed in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.